We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Creating Ideal Neural Cells for Clinical Use
News

Creating Ideal Neural Cells for Clinical Use

Creating Ideal Neural Cells for Clinical Use
News

Creating Ideal Neural Cells for Clinical Use

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Creating Ideal Neural Cells for Clinical Use"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Investigators at the Burnham Institute for Medical Research (Burnham) have developed a protocol to differentiate human embryonic stem cells (hESCs) into neural progenitor cells that may be ideal for transplantation.

The research, conducted by Alexei Terskikh, Ph.D., and colleagues, outlines a method to create these committed neural precursor cells (C-NPCs) that is replicable, does not produce mutations in the cells and could be useful for clinical applications. The research was published on March 13 in the journal Cell Death and Differentiation.

When the C-NPCs created using the Terskikh protocol were transplanted into mice, they became active neurons and integrated into the cortex and olfactory bulb. The transplanted cells did not generate tumor outgrowth.

“The uniform conversion of embryonic stem cells into neural progenitors is the first step in the development of cell-based therapies for neurodegenerative disorders or spinal injuries,” said Dr. Terskikh. “Many of the methods used to generate neural precursor cells for research in the lab would never work in therapeutic applications. This protocol is very well suited for clinical application because it is robust, controllable and reproducible.”

Dr. Terskikh notes that the extensive passaging (moving cells from plate to plate) required by some protocols to expand the numbers of neural precursor cells limits the plasticity of the cells, can introduce mutations and may lead to the expression of oncogenes. The Terskikh protocol avoids this by using efficient conversion of hESCs into primary neuroepithelial cells without the extensive passaging.

This research received funding from the National Institutes of Health and the California Institute for Regenerative Medicine.
Advertisement